•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
AI Use Permeates Dealmaking Despite Operational Concerns: SS&C Intralinks Report
SS&C Intralinks Predicts M&A Deal Flow Resilience in Q1 2025
SS&C Intralinks Predicts M&A Deal Flow Rising Globally in Q4 2024
SS&C Intralinks Releases 2025 Limited Partner Survey Results
Already premium?